ARRIVENT BIOPHARMA, INC. Cash and Restricted Cash
ARRIVENT BIOPHARMA, INC. (AVBP) had Cash and Restricted Cash of $154.68 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $154.68M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $62.10M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $45.54M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $112.67M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $154.68M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $62.10M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $45.54M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $112.67M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $112.77M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $49.87M 10-Q · filed 2026-05-11 |
| 2024-12-31 | $74.29M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $282.86M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $298.67M 10-Q · filed 2025-08-11 |
| 2024-03-31 | $317.39M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $150.39M 10-K · filed 2026-03-05 |
| 2023-09-30 | $141.36M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $157.83M 10-Q · filed 2024-08-14 |
| 2023-03-31 | $191.46M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $163.37M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |